UA84402C2 - Применение монооксида углерода для лечения воспаления почек - Google Patents

Применение монооксида углерода для лечения воспаления почек

Info

Publication number
UA84402C2
UA84402C2 UA20041210106A UA20041210106A UA84402C2 UA 84402 C2 UA84402 C2 UA 84402C2 UA 20041210106 A UA20041210106 A UA 20041210106A UA 20041210106 A UA20041210106 A UA 20041210106A UA 84402 C2 UA84402 C2 UA 84402C2
Authority
UA
Ukraine
Prior art keywords
carbon monoxide
nephritis
treatment
biomarker
spleen
Prior art date
Application number
UA20041210106A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Августин М.К. Чой
Лео Е. Оттербейн
Original Assignee
Йельский Университет
Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йельский Университет, Джонс Хопкинс Юниверсити filed Critical Йельский Университет
Publication of UA84402C2 publication Critical patent/UA84402C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
UA20041210106A 2002-05-09 2002-05-09 Применение монооксида углерода для лечения воспаления почек UA84402C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (fr) 2002-05-09 2002-05-09 Monoxyde de carbone servant de biomarqueur et d'agent therapeutique

Publications (1)

Publication Number Publication Date
UA84402C2 true UA84402C2 (ru) 2008-10-27

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041210106A UA84402C2 (ru) 2002-05-09 2002-05-09 Применение монооксида углерода для лечения воспаления почек

Country Status (13)

Country Link
EP (1) EP1501523A4 (fr)
JP (1) JP2005532314A (fr)
KR (1) KR20040106515A (fr)
CN (1) CN1638781A (fr)
AU (1) AU2002308676B2 (fr)
BR (1) BR0215717A (fr)
CA (1) CA2484770A1 (fr)
EA (1) EA200401478A1 (fr)
MX (1) MXPA04011113A (fr)
NO (1) NO20044865L (fr)
RS (1) RS96904A (fr)
UA (1) UA84402C2 (fr)
WO (1) WO2003094932A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
NZ534912A (en) 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
PL373002A1 (en) 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
CA2481786A1 (fr) 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methodes de traitement de l'enterocolite necrosante neonatale
ATE521357T1 (de) * 2002-05-17 2011-09-15 Univ Yale Verfahren zur behandlung von hepatitis
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
AU2007328549A1 (en) * 2006-12-06 2008-06-12 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
EP3583851A1 (fr) * 2011-01-14 2019-12-25 Children's Hospital Los Angeles Solution de monoxyde de carbone utilisable en vue du traitement d'une maladie, notamment la drépanocytose
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9365419B2 (en) 2011-03-24 2016-06-14 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring alzheimer's disease
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (fr) 2011-07-21 2017-03-22 Alfama, Inc. Molécules libérant du ruthénium-monoxyde de carbone et utilisations de celles-ci
WO2014165732A1 (fr) 2013-04-04 2014-10-09 The Regents Of The University Of California Système et méthode d'utilisation de l'air expiré pour surveiller les états inflammatoires
EP2868348A1 (fr) * 2013-11-04 2015-05-06 Universität Zürich Composés à libération de monoxide de carbone et leurs formulations utiles pour induire la biogenèse mitochondriale et la réparation tissulaire
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
US11576929B2 (en) 2018-06-08 2023-02-14 Sumitomo Seika Chemicals Co., Ltd. Composition for inflammatory gastrointestinal disorders
JP7396598B2 (ja) * 2018-06-08 2023-12-12 住友精化株式会社 皮膚創傷用組成物
WO2020247825A1 (fr) * 2019-06-06 2020-12-10 The General Hospital Corporation Monoxyde de carbone en tant que traitement pour une maladie neurodégénérative
WO2022015986A1 (fr) * 2020-07-16 2022-01-20 Cornell University Méthodes de traitement du cancer métastatique à l'aide de monoxyde de carbone à faible dose
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
DE59710969D1 (de) * 1996-08-27 2003-12-11 Messer Griesheim Gmbh Wasserstoffhaltiges medikament
RU2003131675A (ru) * 2001-03-30 2005-03-10 Сэнгстат Медикал Корпорейшн (Us) Генерирующие моноксид углерода соединения для лечения сосудистых, воспалительных и имунных нарушений

Also Published As

Publication number Publication date
WO2003094932A1 (fr) 2003-11-20
EP1501523A1 (fr) 2005-02-02
NO20044865L (no) 2004-12-07
JP2005532314A (ja) 2005-10-27
MXPA04011113A (es) 2005-02-14
CA2484770A1 (fr) 2003-11-20
EA200401478A1 (ru) 2005-12-29
RS96904A (en) 2007-02-05
CN1638781A (zh) 2005-07-13
EP1501523A4 (fr) 2006-12-13
KR20040106515A (ko) 2004-12-17
BR0215717A (pt) 2005-02-22
AU2002308676B2 (en) 2009-06-11
AU2002308676A1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
UA84402C2 (ru) Применение монооксида углерода для лечения воспаления почек
EP2228654A3 (fr) Diagnostic et traitement de l'invasion des cellules cancéreuses
WO2004078124A3 (fr) Procedes et compositions impliquant mda-7
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
EP1578996A4 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
MX2007013834A (es) Terapias de enfermedades vasculares.
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
WO2004033660A3 (fr) Profilage d'expression genique a partir d'echantillons de type ffpe, fixes par formaline (ff) et imbriques en parafine (pe)
WO2005113831A3 (fr) Biomarqueurs pour la sclerose en plaques et procedes d'utilisation correspondants
HK1121083A1 (en) Methods for reducing blood pressure
NZ546440A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
HK1106246A1 (en) S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s-
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
EP1812007A4 (fr) Composes pyridazine et methodes